{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:17:05Z","timestamp":1792318625293,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["407779\/2021\u20133"],"award-info":[{"award-number":["407779\/2021\u20133"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-01499\u201321"],"award-info":[{"award-number":["APQ-01499\u201321"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.virusres.2023.199291","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T14:14:38Z","timestamp":1702563278000},"page":"199291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19"],"prefix":"10.1016","volume":"340","author":[{"given":"Daisymara Priscila","family":"de Almeida Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Adan Flores","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Vinicius Sousa","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Alves","family":"Clarindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds de F\u00e1tima Silva","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine Lima","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington Alves","family":"De Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nath\u00e1lia Evelyn Morais","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia Maria de","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gata","family":"Lopes-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella Sousa","family":"Co\u00ealho Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Cardoso","family":"Corr\u00eaa-Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Neves","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalita Souza","family":"Arantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Costa Vasconcelos","family":"Litwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Camilo","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus S\u00e1 Magalh\u00e3es","family":"Serafim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Gon\u00e7alves","family":"Maltarollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Carolina","family":"Guatimosim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio Morais","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Salgado","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza Valen\u00e7a","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edel Figueiredo","family":"Barbosa-Stancioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio Guimar\u00e3es","family":"da Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngelo","family":"De F\u00e1tima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana Grazziela Alves","family":"Coelho-dos-Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0001","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-023-37773-6","article-title":"Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment","volume":"14","author":"Abdelnabi","year":"2023","journal-title":"Nat. Commun"},{"key":"10.1016\/j.virusres.2023.199291_bib0002","article-title":"The effort to count the pandemic's global death toll","volume":"601","author":"Adam","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.virusres.2023.199291_bib0003","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem. Soc. Rev"},{"key":"10.1016\/j.virusres.2023.199291_bib0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijpddr.2018.10.002","article-title":"Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity","volume":"25","author":"Aguiar","year":"2018","journal-title":"Int. J. Parasitol-Drugs Drug Resis."},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jmv.26179","article-title":"Use of amantadine in a patient with SARS-CoV-2","volume":"93","author":"Aranda-Abreu","year":"2021","journal-title":"J. Med. Virol"},{"key":"10.1016\/j.virusres.2023.199291_bib0006","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760200342","article-title":"SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network","volume":"115","author":"Araujo","year":"2020","journal-title":"Mem. Inst. Oswaldo. Cruz"},{"issue":"9","key":"10.1016\/j.virusres.2023.199291_bib0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.virusres.2023.199291_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug. Discov"},{"issue":"2","key":"10.1016\/j.virusres.2023.199291_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/v14020201","article-title":"SARS-CoV-2: ultrastructural characterization of Morphogenesis in an In Vitro system","volume":"14","author":"Barreto-Vieira","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virusres.2023.199291_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100086","article-title":"Therapeutics for COVID-19 and post COVID-19 complications: an update","volume":"3","author":"Basu","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug. Discov"},{"issue":"19","key":"10.1016\/j.virusres.2023.199291_bib0012","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.virusres.2023.199291_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106185","article-title":"Viroporins: structure, function, and their role in the life cycle of SARS-CoV-2","volume":"145","author":"Breitinger","year":"2022","journal-title":"Int. J. Biochem. Cell. Biol"},{"key":"10.1016\/j.virusres.2023.199291_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1128157","article-title":"Adamantanes for the treatment of neurodegenerative diseases in the presence of SARS-CoV-2","volume":"17","author":"Butterworth","year":"2023","journal-title":"Front. Neurosci"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0018","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1038\/s41598-020-73162-5","article-title":"Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy","volume":"10","author":"Caldas","year":"2020","journal-title":"Sci. Rep"},{"key":"10.1016\/j.virusres.2023.199291_bib0020","article-title":"Autophagy in severe acute respiratory syndrome coronavirus 2 infection","volume":"29","author":"Chen","year":"2022","journal-title":"Curr. Opin. Physiol"},{"issue":"4","key":"10.1016\/j.virusres.2023.199291_bib0021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat. Microbiol"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0023","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta. Biomed"},{"key":"10.1016\/j.virusres.2023.199291_bib0025","doi-asserted-by":"crossref","first-page":"W53","DOI":"10.1093\/nar\/gku401","article-title":"ProTox: a web server for the in silico prediction of rodent oral toxicity","volume":"42","author":"Drwal","year":"2014","journal-title":"Nucleic. Acids. Res"},{"key":"10.1016\/j.virusres.2023.199291_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug. Resist. Updat"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0027","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1038\/s41598-023-31764-9","article-title":"Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites","volume":"13","author":"Fam","year":"2023","journal-title":"Sci. Rep"},{"issue":"4","key":"10.1016\/j.virusres.2023.199291_bib0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/v13040539","article-title":"Amantadine inhibits SARS-CoV-2 In Vitro","volume":"13","author":"Fink","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virusres.2023.199291_bib0029","article-title":"Molnupiravir, an oral antiviral treatment for COVID-19","author":"Fischer","year":"2021","journal-title":"medRxiv"},{"issue":"628","key":"10.1016\/j.virusres.2023.199291_bib0030","doi-asserted-by":"crossref","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.virusres.2023.199291_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.589505","article-title":"Cathepsin L in COVID-19: from pharmacological evidences to genetics","volume":"10","author":"Gomes","year":"2020","journal-title":"Front. Cell. Infect. Microbiol"},{"issue":"8","key":"10.1016\/j.virusres.2023.199291_bib0033","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cmi.2022.03.030","article-title":"Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19","volume":"28","author":"Girardin","year":"2022","journal-title":"Clin. Microbiol. Infect"},{"issue":"2","key":"10.1016\/j.virusres.2023.199291_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5114\/fn.2021.107572","article-title":"Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?","volume":"59","author":"Grieb","year":"2021","journal-title":"Folia. Neuropathologica"},{"issue":"10319","key":"10.1016\/j.virusres.2023.199291_bib0036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","article-title":"Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management","volume":"399","author":"Heskin","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.virusres.2023.199291_bib0037","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"7944","key":"10.1016\/j.virusres.2023.199291_bib0038","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell. Biol"},{"issue":"3","key":"10.1016\/j.virusres.2023.199291_bib0040","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/jmv.26397","article-title":"Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells","volume":"93","author":"Ko","year":"2021","journal-title":"J. Med. Virol"},{"key":"10.1016\/j.virusres.2023.199291_bib0042","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.virusres.2023.199291_bib0043","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ofid\/ofaa105","article-title":"Coronavirus disease 2019 treatment: a review of early and emerging options","volume":"7","author":"McCreary","year":"2020","journal-title":"Open. Forum. Infect. Dis"},{"issue":"5","key":"10.1016\/j.virusres.2023.199291_bib0044","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging pandemic diseases: how we got to COVID-19","volume":"3","author":"Morens","year":"2020","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.virusres.2023.199291_bib0045","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.virusres.2023.199291_bib0046","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro2820","article-title":"Viroporins: structure and biological functions","volume":"10","author":"Nieva","year":"2012","journal-title":"Nat. Rev. Microbiol"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0048","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/2666796701999200713192912","article-title":"Amantadine might be used as a drug for SARS-Cov-2 treatment?","volume":"2","author":"Ozunal","year":"2021","journal-title":"Coronaviruses"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100542","article-title":"Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review","volume":"17","author":"Pantale\u00e3o","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.virusres.2023.199291_bib0050","unstructured":"Pfizer Inc, 2021. Pfizer announces additional phase 2\/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [press release]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase23-study-results (accessed 25 December 2021)."},{"issue":"9","key":"10.1016\/j.virusres.2023.199291_bib0051","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule Pharmacokinetic and Toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0053","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov"},{"key":"10.1016\/j.virusres.2023.199291_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102163","article-title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment","volume":"42","author":"Rejdak","year":"2020","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.virusres.2023.199291_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106755","article-title":"The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): study rationale and design","volume":"116","author":"Rejdak","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.virusres.2023.199291_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628144","article-title":"Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection","volume":"8","author":"Sahoo","year":"2021","journal-title":"Front. Mol. Biosci"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0059","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and Nirmatrelvir-Ritonavir: oral coronavirus disease antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin. Infect. Dis"},{"issue":"2 & 3","key":"10.1016\/j.virusres.2023.199291_bib0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/ijmr.IJMR_1029_20","article-title":"First isolation of SARS-CoV-2 from clinical samples in India","volume":"151","author":"Sarkale","year":"2020","journal-title":"Indian J. Med. Res"},{"issue":"6","key":"10.1016\/j.virusres.2023.199291_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106004","article-title":"Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment","volume":"55","author":"Smieszek","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virusres.2023.199291_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi","year":"2020","journal-title":"Eur. J. Pharmacol"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0063","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s42003-021-02866-9","article-title":"Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro","volume":"4","author":"Toft-Bertelsen","year":"2021","journal-title":"Commun. Biol"},{"issue":"6554","key":"10.1016\/j.virusres.2023.199291_bib0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"Tummino","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.virusres.2023.199291_bib0068","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/cr100264t","article-title":"The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives","volume":"113","author":"Wanka","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.virusres.2023.199291_bib0069","unstructured":"World Health Organization (WHO). 2023. Coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/ (accessed 3 September 2023)."},{"key":"10.1016\/j.virusres.2023.199291_bib0070","unstructured":"World Health Organization (WHO). 2021. Weekly epidemiological update on COVID-19 - 23 November 2021, ed 67. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19-23-november-2021 (accessed 04 July 2023)."},{"key":"10.1016\/j.virusres.2023.199291_bib0071","unstructured":"World Health Organization (WHO). 2023. Weekly epidemiological update on COVID-19 - 19 January 2023, ed 126. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19-19-january-2023 (accessed 04 July 2023)."},{"key":"10.1016\/j.virusres.2023.199291_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101393","article-title":"Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains","volume":"43","author":"Zhang","year":"2022","journal-title":"Nano. Today"},{"issue":"1","key":"10.1016\/j.virusres.2023.199291_bib0073","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target Ther"},{"issue":"10","key":"10.1016\/j.virusres.2023.199291_bib0074","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/v13102082","article-title":"Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the treatment of SARS-CoV-2 In Vitro","volume":"13","author":"Zhou","year":"2021","journal-title":"Viruses"},{"issue":"51","key":"10.1016\/j.virusres.2023.199291_bib0075","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:10:52Z","timestamp":1769713852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170223002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"alternative-id":["S0168170223002538"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199291","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199291"}}